Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise in liver cancer trial

NCT ID NCT05359861

Disease control Sponsor: Coherus Oncology, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically removed and had spread. Researchers compared the triple combination against the standard two drugs plus a placebo to see if it improved progression-free survival and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SRF388 (an experimental drug) combined with atezolizumab (Tecentriq) and bevacizumab (Avastin)
What this could lead to
If it works, this combination could offer a new first-line treatment option for people with advanced liver cancer that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial (30 people) with no results yet. The experimental drug may not improve outcomes over standard therapy, and side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Started

Apr 2022

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Abbreviated Inclusion Criteria: * ≥ 18 years of age on day of signing informed consent * Unresectable locally advanced or metastatic HCC * No prior systemic treatment for unresectable locally advanced or metastatic HCC * BCLC Stage B or Stage C disease * Child-Pugh Class A disease * ≥ 1 measurable lesion per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Laboratory values indicative of adequate organ function as defined in the protocol * Women of childbearing potential must have a negative pregnancy test within 1 week prior to first dose of study drug * Women of childbearing potential or men with a heterosexual partner of childbearing potential or pregnant must agree to refrain from sexual intercourse or be willing to use effective methods of contraception as defined in the protocol while receiving study drug and for 6 months after the last dose of any study drug Abbreviated Exclusion Criteria: * Currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. * Previously received an anti-interleukin (IL)-27 antibody (Ab) or anti-IL-27-targeted therapy. * Received prior systemic therapy for unresectable or metastatic disease. (Note: Prior systemic therapies administered for neoadjuvant, adjuvant, or curative intent (localized disease) are permitted if they were given \> 1 year prior to the development of recurrent or metastatic disease) * Known fibrolamellar HCC histology, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. * Moderate or severe ascites * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) * History of or current hepatic encephalopathy * Unable to undergo disease evaluation with a triphasic CT or MRI because of contrast allergy or other contraindication * Untreated or incompletely treated varices with bleeding or high risk for bleeding. * Symptomatic or untreated brain metastases or leptomeningeal carcinomatosis. * Active or history of autoimmune disease or immune deficiency with some exceptions such as controlled thyroid disease, Type 1 diabetes, eczema and other minor skin disorders. * Medical conditions requiring chronic steroid therapy (ie, \> 10 mg/day of prednisone or its equivalent) or anticipates the need for systemic immunosuppressive medications during treatment with study drug * Known active infection with HIV * Known infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), except for controlled active HBV or fully treated HCV infection as defined by the protocol * Inadequately controlled arterial hypertension

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Ajou University Hospital

    Gyeonggi-do, 443-721, South Korea

  • Buddhist Tzu Chi General Hospital - Hualien Tzu Chi Medical Center

    Hualien City, 970, Taiwan

  • CHA University - Bundang CHA General Hospital (CHA Bundang Medical Center)

    Gyeonggi-do, 463-712, South Korea

  • Chang Gung Memorial Hospital - Kaohsiung Branch

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Chonnam National University (CNU) - Chonnam National University Hwasun Hospital (CNUHH)

    Gwangju, 58128, South Korea

  • City of Hope

    Duarte, California, 91010, United States

  • Daegu Catholic University Medical Center (DCUMC)

    Daegu, 705-718, South Korea

  • E-Da Cancer Hospital

    Kaohsiung City, 82445, Taiwan

  • Gangnam Severance Hospital - Cancer Hospital

    Seoul, 135-720, South Korea

  • Gold Coast Private Hospital

    Southport, 4215, Australia

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Kaohsiung Medical University - Chung-Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Korea University Medical Center - Korea University Anam Hospital

    Seoul, 136-705, South Korea

  • Louisville VA Medical Center - Robley Rex VA Medical Center

    Louisville, Kentucky, 40206, United States

  • NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center (NYU Cancer Institute (NYUCI))

    New York, New York, 10016, United States

  • National Taiwan University Hospital

    Taipei, 10002, Taiwan

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Pusan National University Yangsan Hospital

    Yangsan, 50612, South Korea

  • Royal Melbourne Hospital

    Melbourne, Australia

  • Sarah Cannon Research Institute - Tennessee Oncology

    Chattanooga, Tennessee, 37404, United States

  • Sarah Cannon Research Institute - Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • Seoul National University Bundang Hospital

    Seongnam, 13620, South Korea

  • Seoul National University Hospital (SNUH) - SMG-SNU Boramae Medical Center

    Seoul, 156-707, South Korea

  • Severance Hospital

    Seoul, 03722, South Korea

  • St George Hospital -Kogarah

    Kogarah, 2217, Australia

  • The Alfred Hospital

    Melbourne, 3004, Australia

  • The Catholic University of Korea - St. Vincent's Hospital

    Suwon, Gyeonggi-do, 442-723, South Korea

  • University of Arizona Cancer Center - North Campus

    Tucson, Arizona, 85719, United States

  • University of Florida Health Science Center - Gainesville

    Gainesville, Florida, 32610, United States

  • University of Miami, Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • University of Michigan Health System (UMHS)

    Ann Arbor, Michigan, 48109, United States

  • University of Oklahoma Health Sciences Center - Stephenson Cancer Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Southern California - Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Ulsan College of Medicine - Asan Medical Center (AMC)

    Seoul, 138-736, South Korea

  • Veterans Affairs Ann Arbor Healthcare System

    Ann Arbor, Michigan, 48105, United States

  • Veterans Affairs New York Harbor Healthcare System - Manhattan VA Medical Center

    New York, New York, 10010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.